Abstract: The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.
Abstract: Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as biomarkers for prognosis of sepsis and other diseases.
Type:
Application
Filed:
January 31, 2019
Publication date:
July 18, 2019
Applicant:
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Inventors:
Charles T. ESMON, Jun XU, Xiaomei ZHANG
Abstract: Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as biomarkers for prognosis of sepsis and other diseases.
Type:
Grant
Filed:
June 9, 2015
Date of Patent:
July 16, 2019
Assignee:
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Inventors:
Charles T. Esmon, Jun Xu, Xiaomei Zhang
Abstract: Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as biomarkers for prognosis of sepsis and other diseases.
Type:
Grant
Filed:
May 6, 2014
Date of Patent:
March 26, 2019
Assignee:
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Inventors:
Charles T. Esmon, Jun Xu, Xiaomei Zhang
Abstract: The present invention provides 5-nitrofuran-2-amide derivatives and methods of using the same in the treatment of cancer and induction of apoptosis by activating C/EBP-homologous protein expression.
Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
Type:
Grant
Filed:
June 23, 2017
Date of Patent:
October 30, 2018
Assignees:
Hough Ear Institute, Oklahoma Medical Research Foundation
Inventors:
Richard D. Kopke, Robert A. Floyd, Rheal Towner
Abstract: The present disclosure describes the use peptides of comprising ubiquitin interacting motifs (UIMs) alone or in combination with other agents to treat conditions such as cancer, atherosclerosis and obesity.
Abstract: Disclosed here is a method of transporting a therapeutic or diagnostic agent across a blood-brain barrier or a blood-cochlear barrier or a blood-cerebrospinal fluid barrier of a subject, comprising administering to a subject an amount of a therapeutic and/or diagnostic agent, along with an amount of 2,4-disulfonyl a-phenyl tertiary butyl nitrone (2,4-DSPBN), said therapeutic and/or diagnostic agent being characterized as being unable or poorly able, in the absence of said amount of 2,4-DSPBN, to cross the blood-brain barrier or the blood-cochlear barrier or the blood-cerebrospinal fluid barrier of said subject.
Type:
Application
Filed:
September 14, 2016
Publication date:
September 13, 2018
Applicants:
Oklahoma Medical Research Foundation, Hough Ear Institute
Abstract: Hypercoagulable and hyperinflammatory responses can lead to a variety of diseases including but not limited to disseminated intravascular coagulation in sepsis, consumptive coagulopathy in trauma, thrombosis in the postsurgical setting, acute respiratory distress syndrome in lung, and other diseases or conditions. Polyphosphate is accumulated by many infectious microorganisms and may be released by damaged infectious microorganisms. In addition, polyphosphate is found in many organs and is released from activated platelets and mast cells. Polyphosphates activate the intrinsic pathway of coagulation that also induces inflammation. Hypercoagulable and hyperinflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death, which occur in many pathological conditions.
Type:
Application
Filed:
August 20, 2015
Publication date:
August 30, 2018
Applicants:
OKLAHOMA MEDICAL RESEARCH FOUNDATION, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOI S
Inventors:
Charles T. ESMON, Naomi L. ESMON, James H. MORRISSEY
Abstract: The present disclosure is directed to antibodies binding to ELTDI. Plexin-B2, Spondin-1, fibulin-1, LINGO I or SLIT3 and methods of using such antibodies to treat and/or diagnose gliomas. Thus, in accordance with the present disclosure, there is provided a method of inhibiting a glioma cell comprising contacting said glioma cell with a first antibody or antibody fragment that binds immunologically to ELTDI, Plexin-B2, Spondin-1 or SLIT3. The method may further comprise contacting said glioma cell with a second anti-cancer agent or treatment.
Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
Type:
Grant
Filed:
January 27, 2017
Date of Patent:
July 17, 2018
Assignees:
Hough Ear Institute, Oklahoma Medical Research Foundation
Inventors:
Richard D. Kopke, Robert A. Floyd, Rheal Towner
Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.
Abstract: Therapies using IL-18 alone or in combination with IL-7 for rebuilding weakened immune systems by increasing progenitor cell yields from bone marrow stem cells and/or increasing stem cell engraftment in bone marrow.
Type:
Grant
Filed:
November 20, 2015
Date of Patent:
April 24, 2018
Assignees:
The Board of Regents of the University of Oklahoma, Oklahoma Medical Research Foundation
Inventors:
Tracy Kent Teague, Jonathan D. Wren, Siva Kumar Gandhapudi, Julie Harris Marino, Chibing Tan, Ashlee Allison Rempel, Charles Justin Van De Wiele
Abstract: Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as biomarkers for prognosis of sepsis and other diseases.
Type:
Application
Filed:
December 12, 2017
Publication date:
April 5, 2018
Applicant:
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Inventors:
Charles T. ESMON, Jun XU, Xiaomei ZHANG
Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
Type:
Application
Filed:
June 23, 2017
Publication date:
October 5, 2017
Applicants:
HOUGH EAR INSTITUTE, OKLAHOMA MEDICAL RESEARCH FOUNDATION
Inventors:
Richard D. KOPKE, Robert A. FLOYD, Rheal TOWNER
Abstract: The present disclosure provides for the diagnosis and prediction of neuromyelitis optica (NMO) in subject. It also provides for treatment of multiple sclerosis (MS) in a subject. Thus, in accordance with the present disclosure, there is provided a method for treating a subject having neuromyelitis optica (NMO) comprising administering to said subject an inhibitor of B-cell activating factor (BAFF) and/or an inhibitor or proliferating inducing ligand (APRIL).
Abstract: The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating AAT systemically to the body should work equally well.
Type:
Application
Filed:
April 24, 2017
Publication date:
August 10, 2017
Applicants:
Hough Ear Institute, OKLAHOMA MEDICAL RESEARCH FOUNDATION
Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
Type:
Application
Filed:
January 27, 2017
Publication date:
July 20, 2017
Applicants:
HOUGH EAR INSTITUTE, OKLAHOMA MEDICAL RESEARCH FOUNDATION
Inventors:
Richard D. KOPKE, Robert A. FLOYD, Rheal TOWNER
Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
Type:
Grant
Filed:
February 18, 2016
Date of Patent:
May 9, 2017
Assignees:
Hough Ear Institute, Oklahoma Medical Research Foundation
Inventors:
Richard D. Kopke, Robert A. Floyd, Rheal Towner
Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.